Sprott Inc. (“Sprott” or the “Company”) (NYSE/TSX: SII) today announced that the Toronto Stock Exchange (“TSX”) has approved the Company’s notice of intention to make a normal course issuer bid ("NCIB ...
Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression remains on track for Q2 2026 following successful End‑of‑Phase 2 meeting with the U.S. Food and Drug AdministrationOn-t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results